Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

Abstract While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide clinical management based on molecular biomarkers. To...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Frank P. Lin, Subotheni Thavaneswaran, John P. Grady, Mandy Ballinger, Maya Kansara, Samantha R. Oakes, Jayesh Desai, Chee Khoon Lee, John Simes, David M. Thomas
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6a749ceadf654e848f7ee68f6d873817
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6a749ceadf654e848f7ee68f6d873817
record_format	dspace
spelling	oai:doaj.org-article:6a749ceadf654e848f7ee68f6d8738172021-12-02T18:02:41ZCriteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology10.1038/s41698-021-00194-z2397-768Xhttps://doaj.org/article/6a749ceadf654e848f7ee68f6d8738172021-06-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00194-zhttps://doaj.org/toc/2397-768XAbstract While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide clinical management based on molecular biomarkers. To this end, we have structured a compendium of approved and experimental therapies with associated biomarkers following a survey of drug regulatory databases, existing knowledge bases, and published literature. Each biomarker-disease-therapy triplet was categorised using a tiering system reflective of key therapeutic considerations: approved and reimbursed therapies with respect to a jurisdiction (Tier 1), evidence of efficacy or approval in another jurisdiction (Tier 2), evidence of antitumour activity (Tier 3), and plausible biological rationale (Tier 4). Two resistance categories were defined: lack of efficacy (Tier R1) or antitumor activity (Tier R2). Based on this framework, we curated a digital resource focused on drugs relevant in the Australian healthcare system (TOPOGRAPH: Therapy Oriented Precision Oncology Guidelines for Recommending Anticancer Pharmaceuticals). As of November 2020, TOPOGRAPH comprised 2810 biomarker-disease-therapy triplets in 989 expert-appraised entries, including 373 therapies, 199 biomarkers, and 106 cancer types. In the 345 therapies catalogued, 84 (24%) and 65 (19%) were designated Tiers 1 and 2, respectively, while 271 (79%) therapies were supported by preclinical studies, early clinical trials, retrospective studies, or case series (Tiers 3 and 4). A companion algorithm was also developed to support rational, context-appropriate treatment selection informed by molecular biomarkers. This framework can be readily adapted to build similar resources in other jurisdictions to support therapeutic decision-making.Frank P. LinSubotheni ThavaneswaranJohn P. GradyMandy BallingerMaya KansaraSamantha R. OakesJayesh DesaiChee Khoon LeeJohn SimesDavid M. ThomasNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Frank P. Lin Subotheni Thavaneswaran John P. Grady Mandy Ballinger Maya Kansara Samantha R. Oakes Jayesh Desai Chee Khoon Lee John Simes David M. Thomas Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
description	Abstract While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide clinical management based on molecular biomarkers. To this end, we have structured a compendium of approved and experimental therapies with associated biomarkers following a survey of drug regulatory databases, existing knowledge bases, and published literature. Each biomarker-disease-therapy triplet was categorised using a tiering system reflective of key therapeutic considerations: approved and reimbursed therapies with respect to a jurisdiction (Tier 1), evidence of efficacy or approval in another jurisdiction (Tier 2), evidence of antitumour activity (Tier 3), and plausible biological rationale (Tier 4). Two resistance categories were defined: lack of efficacy (Tier R1) or antitumor activity (Tier R2). Based on this framework, we curated a digital resource focused on drugs relevant in the Australian healthcare system (TOPOGRAPH: Therapy Oriented Precision Oncology Guidelines for Recommending Anticancer Pharmaceuticals). As of November 2020, TOPOGRAPH comprised 2810 biomarker-disease-therapy triplets in 989 expert-appraised entries, including 373 therapies, 199 biomarkers, and 106 cancer types. In the 345 therapies catalogued, 84 (24%) and 65 (19%) were designated Tiers 1 and 2, respectively, while 271 (79%) therapies were supported by preclinical studies, early clinical trials, retrospective studies, or case series (Tiers 3 and 4). A companion algorithm was also developed to support rational, context-appropriate treatment selection informed by molecular biomarkers. This framework can be readily adapted to build similar resources in other jurisdictions to support therapeutic decision-making.
format	article
author	Frank P. Lin Subotheni Thavaneswaran John P. Grady Mandy Ballinger Maya Kansara Samantha R. Oakes Jayesh Desai Chee Khoon Lee John Simes David M. Thomas
author_facet	Frank P. Lin Subotheni Thavaneswaran John P. Grady Mandy Ballinger Maya Kansara Samantha R. Oakes Jayesh Desai Chee Khoon Lee John Simes David M. Thomas
author_sort	Frank P. Lin
title	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
title_short	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
title_full	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
title_fullStr	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
title_full_unstemmed	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
title_sort	criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6a749ceadf654e848f7ee68f6d873817
work_keys_str_mv	AT frankplin criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology AT subothenithavaneswaran criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology AT johnpgrady criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology AT mandyballinger criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology AT mayakansara criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology AT samantharoakes criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology AT jayeshdesai criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology AT cheekhoonlee criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology AT johnsimes criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology AT davidmthomas criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology
_version_	1718378870513598464

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

Ejemplares similares